Dextrose
10 g/100mL · Injection, Solution, Concentrate
- Prescription only
- Active substance
- Dextrose Monohydrate
- Made by
- ICU Medical, Inc.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
At a glance
Quoted from the official label · 2025-11-01
Pharmacies may have trouble getting it. Your pharmacist can suggest what to do. · Updated 2026-09-22 FDA drug shortages
- 10% Dextrose Injection, USP (concentrated dextrose in water) in a partial-fill container is indicated for admixture with amino acids or dilution with other compatible IV fluids to provide a 5% final dextrose…
The maximum rate at which dextrose can be infused without producing glycosuria is 0.5 g/kg of body weight /hr.
Full directions ↓A concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present nor in the presence of delirium tremens if the patient is already dehydrated.
All warnings ↓- Prescription only
- FDA enforcement reports list no ongoing recall, and none from the last two years, for this product code · checked 2026-10-02
Every line above is selected, not written, from the official label. Nothing is reworded. DailyMed
What it is for
- 10% Dextrose Injection, USP (concentrated dextrose in water) in a partial-fill container is indicated for admixture with amino acids or dilution with other compatible IV fluids to provide a 5% final dextrose concentration for intravenous infusion in patients whose condition requires parenteral nutrition.
From the official label · 2025-11-01 · DailyMed
How it works
From this product’s own US prescribing label.
When administered intravenously, solutions containing carbohydrate in the form of dextrose restore blood glucose levels and provide calories.
Carbohydrate in the form of dextrose may aid in minimizing liver glycogen depletion and exerts a protein sparing action.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-11-01
Do not take it if
- A concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present nor in the presence of delirium tremens if the patient is already dehydrated.
- Dextrose Injection, USP without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility that pseudoagglutination of red cells may occur.
Quoted from the official label, section “Contraindications”.
How to take it
These directions are for this exact strength and form. Another one is different.
- Concentrated Dextrose in Water is administered by slow intravenous infusion (a) after admixture with amino acid solutions or (b) after dilution with other compatible IV fluids.
- Dosage should be adjusted to meet the requirements of each individual patient.
- The maximum rate at which dextrose can be infused without producing glycosuria is 0.5 g/kg of body weight /hr.
- About 95% of the dextrose is retained when infused at a rate of 0.8 g/kg/hr.
- Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.
- A list of nutritional admixture values is appended.
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
- (See PRECAUTIONS ).
- Drug Interaction Additives may be incompatible.
- Consult with pharmacist, if available.
- When introducing additives, use aseptic technique, mix thoroughly and do not store.
- Some opacity of the plastic due to moisture absorption during sterilization process may be observed.
- This is normal and does not affect the solution quality or safety.
- The opacity will diminish gradually.
- WARNING: Do not use flexible container in series connections.
Quoted from the official label, section “Dosage & Administration”.
Other warnings
- Concentrated dextrose in water should be administered only after suitable dilution.
- Hypertonic dextrose solutions should be given slowly.
- Significant hyperglycemia and possible hyperosmolar syndrome may result from too rapid administration.
- The physician should be aware of the symptoms of hyperosmolar syndrome, such as mental confusion and loss of consciousness, especially in patients with chronic uremia and those with known carbohydrate intolerance.
- The intravenous administration of this solution can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.
- WARNING : This product contains aluminum that may be toxic.
- Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired.
- Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
- Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity.
- Tissue loading may occur at even lower rates of administration.
- FOR PERIPHERAL VEIN ADMINISTRATION Hypertonic dextrose solutions (above 5% concentration) should be given slowly, preferably through a small bore needle into a large vein, to minimize venous irritation.
- FOR CENTRAL VENOUS ADMINISTRATION Concentrated dextrose should be administered via central vein after appropriate admixture or dilution when required.
- Electrolyte deficits, particularly in serum potassium and phosphate, may occur during prolonged use of concentrated dextrose solutions.
- Blood electrolyte monitoring is essential, and fluid and electrolyte imbalances should be corrected.
- Essential vitamins and minerals also should be provided as needed.
- Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.
- Care should be exercised to insure that the needle (or catheter) is well within the lumen of the vein and that extravasation does not occur.
- Concentrated dextrose solutions should not be administered subcutaneously or intramuscularly.
- Do not administer unless solution is clear and container is undamaged.
- Discard unused portion.
- Pregnancy Category C.
Quoted from the official label, section “Warnings”.
Pregnancy and breastfeeding
- Category C.
- Animal reproduction studies have not been conducted with dextrose.
- It is also not known whether dextrose can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
- Dextrose should be given to a pregnant woman only if clearly needed.
- This product contains no more than 25 mcg/L of aluminum.
Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.
Other medicines
- Drug Interaction Additives may be incompatible.
- Consult with pharmacist, if available.
- When introducing additives, use aseptic technique, mix thoroughly and do not store.
- Some opacity of the plastic due to moisture absorption during sterilization process may be observed.
- This is normal and does not affect the solution quality or safety.
- The opacity will diminish gradually.
- WARNING: Do not use flexible container in series connections.
Quoted from the official label, section “Drug Interactions”.
If you take too much
In an emergency, call your local emergency number or a poison control centre.
In the event of overhydration or solute overload during therapy, re-evaluate the patient and institute appropriate corrective measures. (See WARNINGS and PRECAUTIONS ).
Quoted from the official label, section “Overdosage”.
Side effects
- Hyperosmolar syndrome, resulting from excessively rapid administration of concentrated dextrose may cause hypovolemia, dehydration, mental confusion and/or loss of consciousness.
- Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.
- If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
Quoted from the official label, section “Adverse Reactions”.
What it looks like and how it is packed
- 10% Dextrose Injection, USP is supplied in single-dose, partial-fill, flexible containers as follows:
- a 500 mL volume in a 1000 mL container.
- See the following table.
- Concentrated Dextrose In Water Content and Characteristics NDC No. % Conc.
- Fill Volume (mL) Total Grams of Dextrose Hydrous Per Container kcal Caloric value calculated on the basis of 3.4 kcal/g of dextrose, hydrous. /100 mL (Per Container) mOsmol/liter (calc.) pH (range) 0409-7938-19 10 500 50 34 (170) 505 4.3 (3.2 to 6.5) 0990-7938-19 10 500 50 34 (170) 505 4.3 (3.2 to 6.5) ICU Medical is transitioning NDC codes from the "0409" to a "0990" labeler code.
- Both NDC codes are expected to be in the market for a period of time.
- Nutritional Admixture Values Equal volumes of 10% Dextrose Injection, USP and Aminosyn™ 7% provide the following:
- Dextrose Pre-Dilution Concentration Admixture Non-Protein kcal/g N Admixture Non-Protein kcal/liter Admixture g N/liter Admixture Dextrose Concentration 10% 31 170 5.5 5%
- Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing.
- Revised: November, 2018 EN-4694 ICU Medical, Inc., Lake Forest, Illinois, 60045, USA
Quoted from the official label, section “How Supplied”.
What is in it
- 10% Dextrose Injection, USP (concentrated dextrose in water) is a sterile, nonpyrogenic, hypertonic solution of Dextrose, USP in water for injection for intravenous administration after appropriate admixture or dilution. 10% Dextrose Injection, USP is provided as a 500 mL volume in a 1000 mL partial-fill container. The container is designed to facilitate admixture or dilution. See table under HOW SUPPLIED for summary of content and characteristics of this concentrated solution. The solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only for use as a single-dose injection following admixture or dilution. The flexible plastic container is fabricated from a specially formulated polyvinyl chloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period. Dextrose Injection, USP is a parenteral fluid and nutrient replenisher. Dextrose Injection, USP is chemically designated D-glucose monohydrate (C 6 H 12 O 6
- H 2 O), a hexose sugar freely soluble in water. It has the following structural formula:
- Water for Injection, USP is chemically designated H 2 O. structural formula dextrose
Quoted from the official label, section “Description”.
Ingredients people check for
Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.
The stored label for this product has no list of inactive ingredients. The list on the pack is the one to check.
Quoted from the FDA label. A label that does not name an ingredient is not a guarantee that the product is free of it, and formulations change. With an allergy, check the pack and ask a pharmacist.
Every version of this medicine (2)
The same active substance, strength and kind of form, from every company that sells it — with what each label lists.
Showing 2 of 2
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
CanadaNo exact match for this strength and form
Details
| Made by | ICU Medical, Inc. |
|---|---|
| Active substance | Dextrose Monohydrate |
| Strength | 10 g/100mL |
| Form | Injection, Solution, Concentrate |
| Route | Intravenous |
| Packs | 12 POUCH in 1 CASE / 1 BAG in 1 POUCH / 500 mL in 1 BAG |
| NDC | 0990-7938 |
Source: NDC Directory · 2026-09-13 · not reviewed by a clinician
Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).
Other strengths and forms
42 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- Injection, Solution34 products
- 2.5 g/50mL
5 g/100mL2
5 g/100mL · 2 companies
- 10 g/100mL
- 20 g/100mL
- 30 g/100mL
- 40 g/100mL
50 mg/mL5
- 50 g/1000mL
- 50 g/100mL
70 g/100mL2
70 g/100mL · 2 companies
- 100 g/1000mL
100 mg/mL3
100 mg/mL · 3 companies
250 mg/mL3
250 mg/mL · 3 companies
2500 mg/50mL2
2500 mg/50mL · 2 companies
- 5000 mg/100mL
- 12500 mg/250mL
- 25000 mg/500mL
- Injection4 products
2.5 g/50mL2
2.5 g/50mL · 2 companies
5 g/100mL2
5 g/100mL · 2 companies
- Solution3 products
- Injection, Solution, Concentrate1 products
- 10 g/100mL
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.